latest update:
[TrialBase DB]

trial summary · NCT07728175

Effects of Sirolimus on Asymptomatic ApoE4 Carriers

Effects of Sirolimus on Middle Aged Asymptomatic ApoE4 Carriers

Trial record from the TrialBase DB dataset, status RECRUITING, condition Genetic Predisposition to Disease, sponsored by University of Missouri-Columbia. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07728175phase PHASE1enrollment 225start 2026-12-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure. Sirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life. There will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required. Participants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams

Source record: https://clinicaltrials.gov/study/NCT07728175

Facts

registry idNCT07728175
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionGenetic Predisposition to Disease
sponsorUniversity of Missouri-Columbia
sponsor classOTHER
enrollment225
start date2026-12-01
primary completion2027-12-31
completion2028-07-07
results postednot reported

Conditions

  • Genetic Predisposition to Disease
  • Healthy Volunteer
  • APOE-4 Positive

Interventions

  • Sirolimus (rapamycin)
  • Placebo

Countries

  • United States

Intervention types: DRUG

Work with this record